Researchers Say Abbott Stymied Drug Competitors for Its TriCor – jdsupra.com

The study, published in the Archives of Internal Medicine, estimated that the prolonged exclusivity of brand-name formulations of fenofibrate cost the U.S. health-care system approximately $700 million per year. Sometimes, drug companies pay off potential …

Posted in Uncategorized